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study question: In girls and adolescents with Turner syndrome (TS), is there a correlation between serum AMH levels and karyo-
type, spontaneous puberty and other biochemical markers of ovarian function, or growth hormone (GH) therapy?
summary answer: Serum anti-Mu¨llerian hormone (AMH) correlates with karyotype, pubertal development, LH, FSH and are meas-
urable in a higher percentage of TS patients under GH therapy.
what is known already: Most girls with TS suffer from incomplete sexual development, premature ovarian failure and infertility
due to abnormal ovarian folliculogenesis. Serum AMH levels reﬂect the ovarian reserve in females, even in childhood.
study design, size, duration: Cross-sectional study investigating 270 karyotype proven TS patients aged 0–20 years between
2009 and 2010.
participants/materials, settings, methods: Studies were conducted at three University Children’s hospitals in
Europe. Main outcome measures were clinical data concerning pubertal development as well as laboratory data including karyotype,
serum AMH, LH, FSH, estradiol (E2), inhibin B and IGF.
results and the role of chance: Serum AMH was detectable in 21.9% of all TS girls and correlated strongly with karyotypes.
A measurable serum AMH was found in 77% of TS girls with karyotype 45,X/46,XX, in 25% with ‘other’ karyotypes and in only 10% of
45,X TS girls. A strong relationship was also observed for measurable serum AMH and signs of spontaneous puberty such as breast devel-
opment [adjusted odds ratio (OR) 19.3; 95% CI 2.1–175.6; P ¼ 0.009] and menarche (crude OR 47.6; 95% CI 4.8–472.9; P ¼ 0.001).
Serum AMH correlated negatively with FSH and LH, but did not correlate with E2 and inhibin B. GH therapy increased the odds of
having measurable AMH in TS (adjusted OR 4.1; 95% CI 1.9–8.8; P, 0.001).
limitations, reasons for caution: The cross-sectional design of the study does not allow longitudinal interpretation of the
data; for that further studies are needed. High percentage of non-measurable AMH levels in the cohort of TS require categorized analysis.
wider implications of the findings: Serum AMH levels are a useful marker of the follicle pool and thus ovarian function in
pediatric patients with TS. These ﬁndings are in line with the published literature. The ﬁnding that GH therapy may affect AMH levels is novel,
but must be conﬁrmed by future longitudinal studies.
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Introduction
Turner syndrome (TS) is found in 1:2000 newborn girls. The classic
form is associated with the 45,X karyotype (50%), whereas variants
either show a mosaic of 45,X/46,XX (25%) or have structural anom-
alies of the X chromosome such as deletions, iso- or ring chromo-
somes (25%) (Saenger et al., 2001; Bondy, 2007). The clinical
spectrum of TS is broad and highly variable but short stature and
gonadal dysgenesis are characteristic features. Gonadal dysgenesis in
TS results in pubertal delay or failure and infertility in most patients.
However, up to 30% of girls with TS have spontaneous pubertal de-
velopment and 2–5% have regular menstrual cycles before the
onset of premature menopause (Abir et al., 2001). Spontaneous preg-
nancies occur only in 2% of women with TS, mostly at a young age
(23–24 years) and appear to be associated with the mosaic karyotype
(Hovatta, 1999).
Primary ovarian insufﬁciency (POI) in patients with TS is due to an
accelerated loss of follicles from the ovaries which may start as early as
18 weeks into fetal life (Weiss, 1971; Santoro, 2003; Reynaud et al.,
2004). More recent studies found that there may be viable follicles
even in the ovaries of 12–13-year-old girls with classical TS without
spontaneous pubertal development (Gravholt et al., 2002; Hreinsson
et al., 2002), although the quality of these follicles is doubtful. Thus,
preservation of fertility in patients with TS may be feasible through
cryopreservation of ovarian tissue before follicles begin to disappear
(Rutherford and Matthews 2000; Huang et al., 2008). However, to de-
termine the possible candidates among girls and young adolescents
with TS and the right time point for such interventions, biochemical
markers reﬂecting the ovarian reserve in childhood are needed.
Antral follicle count (AFC) and early follicular phase serum levels of
FSH, inhibin B and estradiol (E2) are measured to assess a woman’s
ovarian reserve (Burger et al., 1995). However, all these methods to
assess the ovarian reserve are based on the mature, adult female
hypothalamic–pituitary–gonadal axis. In contrast, GnRH is switched
off after birth and remains silent until the age of 10 years when
healthy girls start puberty. During this time FSH, inhibin B and E2
levels are low. Although gonadotrophin levels (FSH and LH) tend to
be higher in patients with TS, especially in the ﬁrst 2–5 years of life,
a signiﬁcant overlap exists between TS and normal girls especially
during mid-childhood (Conte et al., 1975; Chrysis et al., 2006;
Hagen et al., 2010b). Therefore, gonadotrophin levels may not
reﬂect the ovarian reserve before the onset of puberty.
In the past, we and others have shown that the serum anti-Mu¨llerian
hormone (AMH) level is a good marker for the size of the growing fol-
licle pool, and, indirectly, also of the primordial follicle pool, reﬂecting
the ovarian reserve (de Vet et al., 2002; van Rooij et al., 2002; van
Rooij et al., 2005; Pigny et al., 2006; Visser et al. 2006). AMH is spe-
ciﬁcally expressed in granulosa cells of growing non-selected follicles.
In women of reproductive age, serum AMH levels correlate strongly
with AFC and levels decline over time to become undetectable at
menopause. Recent studies in healthy normo-ovulatory adult
women conﬁrmed this decline in serum AMH with increasing age
(Kelsey et al., 2011; Lie Fong et al., 2012). Interestingly, this decline
in serum AMH levels precedes the changes in traditional markers
for ovarian reserve, such as FSH, inhibin B and E2. Hence, it is believed
that serum AMH levels constitute an ovarian reserve marker in adult
women, independent from the HPG axis.
Serum AMH levels have been assessed in healthy females through-
out life span and have been studied in two independent groups of
patients with TS (Borgstrom et al., 2009; Hagen et al., 2010a).
During childhood AMH levels increase slightly from birth onward
and plateau during adolescence, suggesting that follicle dynamics in
children may differ from that in adults. Not until the age of 25, the
decline in serum AMH with increasing age is observed (Hagen et al.,
2010a; Kelsey et al., 2011; Lie Fong et al. 2012). Nevertheless, assess-
ment of serum AMH, also at a young age, is indicative of ongoing fol-
licular development (Visser et al. 2012). In this European Society of
Pediatric Endocrinology collaborative study, we measured serum
AMH levels in 270 TS girls and correlated the values to age, karyo-
types, pubertal development and to biochemical markers of gonadal
function (serum LH, FSH, inhibin B and E2). In addition, we addressed
the question whether recombinant human growth hormone (rhGH)
therapy, which is recommended in TS to improve growth, may inﬂu-
ence serum AMH levels in TS.
Methods
Patients and ethical approval
TS subjects were recruited for the study at three European pediatric endo-
crine units in Bern (Switzerland), Rotterdam (The Netherlands) and Tu¨bin-
gen (Germany). Most patients’ data were available from registries: TS
registry (Tu¨bingen; n ¼ 109; inclusion rate 109/117) and a national
growth hormone (GH) registry (Rotterdam; n ¼ 140; inclusion rate
140/142). In Bern, TS patients (n ¼ 21; inclusion rate 21/21) were
recruited during their regular medical follow-up visits between 2009 and
2010. Small amounts of properly stored serum were available for labora-
tory studies. The study was approved by the local ethical authorities of all
three study centers. All patient and parents gave informed consent. The
primary inclusion criteria for the study consisted of the diagnosis of TS
based on a state-of-the art karyotype, clinical data (for details see Table I)
and a serum sample for the determination of hormone measurements.
Criteria and deﬁnitions for grouping and analyses of the data were as
follows: patients were divided into three groups according to their karyo-
type group: 45,X, 45,X/46,XX or other. Among the group ‘other karyo-
type’ additional subgroups were formed according to geneticists’
recommendation shown in Table II. Analyses for spontaneous puberty
and spontaneous menarche (yes/no) included only TS subjects 12 years
and older who had no sex hormone replacement (estrogen) therapy.
Breast development Tanner stage B2 or more was taken as deﬁnition
for spontaneous pubertal development (Tanner and Whitehouse, 1976).
As a control population, we used healthy girls and adolescents aged
0–20 years (n ¼ 252) of our nomogram study (Lie Fong et al., 2012).
Detailed information on recruitment strategy and study populations are
available in the original paper (Lie Fong et al., 2012).
Laboratory methods
All patients provided a document of the exact G-band karyotype of their
blood lymphocytes performed at their treatment center which generally
included at least counting of 30 metaphases. LH and FSH were measured
by immunochemiluminometric assays (Roche Modular E170, Hoffmann-La
Roche Ltd., Basel, Switzerland) at each center and results were provided
as IU/l. E2 was determined by a radioimmunoassay in pmol/l (Siemens
Global Healthcare Diagnostics, Inc., former Diagnostic Products Corpor-
ation). Serum insulin-like growth factor-1 (IGF-1) was also determined
by a commercially available kit (Nichols Institute Diagnostics, Bad Vilbel,
Germany). For AMH and inhibin measurements, all serum samples were
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frozen and stored under standardized conditions before they were collect-
ively sent to the laboratory of JAV in Rotterdam. Inhibin B (pg/ml) was
determined in all serum samples with measurable AMH by an enzyme im-
munoassay (Oxford Bio-Innovation Ltd, Oxfordshire, UK). AMH (ng/ml)
was determined in Rotterdam by an in-house developed AMH-ELISA
(enzyme-linked immunosorbent assay; commercially available as the
GenII Beckmann Coulter, Beckman Coulter, Inc.) (Kevenaar et al.,
2006). Previously, we have shown that AMH immunoreactivity in serum
is stable during storage and after repeated freeze–thaw cycles (Al-Qahtani
et al., 2005; Kevenaar et al., 2006), thus neither storage nor transport
should affect measured AMH concentrations. This highly sensitive ELISA
uses AMH standards in the range of 5–0.037 ng/ml. Of note, serum
AMH measurement of the control population was performed with the
same assay. Intra- and inter-assay coefﬁcients of variation were ,3 and
8% for FSH, 5 and 6% for LH, 5 and 7% for E2, 9 and 15% for inhibin
B, 5 and 9% for IGF-1, and 5 and 10% for AMH.
Statistical analysis
Associations between AMH, age (linear and quadratic terms), karyotype
and GH therapy were assessed in a multivariable logistic model with meas-
urable AMH as outcome; therefore, all pairwise associations are adjusted
for the other co-factors. Correlations between measurable AMH and
spontaneous puberty in TS girls aged 12 years or older were calculated
from logistic models with spontaneous puberty as outcome. The associ-
ation with breast development was adjusted for age (linear term only),
additional adjustment for karyotype was not possible. Adjustment for
the association of AMH with menarche was not possible and is thus
shown crude. The relationships between AMH and other hormones
(FSH, LH, E2 and inhibin B) were each assessed in a logistic model with
measurable AMH as outcome and the respective log-transformed
hormone variable as independent factor, adjusting for karyotype and age
(linear and quadratic terms). The correlation between measurable AMH
.............................................................................................................................................................................................
Table I Characteristics of studied patients.
ALL, n (%) No GH, n (%) GH Tx, n (%) P-valuea
Number 270 152 118
Age .12 years, n 120 (44.4) 40 (26.3) 80 (67.8) ,0.001
Karyotype 0.89
45,X 136 (50.4) 75 (49.3) 61 (51.7)
45,X/46,XX 22 (8.2) 12 (7.9) 10 (8.5)
Other 112 (41.5) 65 (42.8) 47 (39.8)
Age, years (mean/SD) 10.8+4.8 8.7+4.2 13.4+4.1 ,0.001
Age at start of GH, years (mean/SD) 7.4+3.1
Spontaneous puberty, n (of 41c)b 22 (53.7) 11 (37.9) 11 (91.7) 0.002
Spontaneous menarche, n (of 47c)b 8 (17.0) 1 (2.9) 7 (58.3) ,0.001
Measurable AMH, n 59 (21.9) 24 (15.8) 35 (29.7) 0.006
AMH level if measurable, ng/ml (mean/SD) 1.86+1.75 2.13+1.95 1.67+1.61 0.33
ax2 test for categorical and t-test for continuous variables.
b.12 years, no HRT.
cData set not available for all subjects.
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Table II Detailed characterization of observed karyotypes and AMH levels.
Categories Subcategories n (%) Measurable AMH [n (%)] OR2 (95% CI2) AMH [ng/ml (median/range)]
45,X 136 (50.4) 14 (10.3) 1 (reference) 0.53 (0.12–2.10)
45,X/46,XX 22 (8.1) 17 (77.3) 37.0 (11.2–122.3) 2.26 (0.24–6.37)
Others 112 (41.5) 28 (25) 3.4 (1.6–7.2) 1.06 (0.04–7.78)
46,X,i(Xq) 40 (14.8) 5 (12.5)
46,X,i(Xp) 4 (1.5) 0
46,X,del(X) 15 (5.6) 8 (53.3)
46,X,r(X) 13 (4.8) 2 (15.4)
45,X/47,XXX 19 (7.0) 8 (42.1)
45,X/46,XY 9 (3.3) 2 (22.2)
‘others’1 12 (4.4) 3 (25)
Notes: Except for 45,X and 45,X/46,XX, the karyotypes include mosaicism of the karyotypes.
(1) ‘Others’ include marker chromosomes (of unknown origin; n ¼ 6), derivatives of X chromosomes (2), translocations involving the X chromosome (2) and complex mixed
mosaicisms (2).
(2) Data are adjusted for GH therapy and linear and quadratic term of age, and relate to measurable versus non-measurable AMH levels.
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and standardized IGF-1 was also calculated from a logistic model adjusting
for the same co-factors.
All P-values and 95% conﬁdence intervals (CI) are two-sided. P-values
,0.05 were considered signiﬁcant. All analyses were done using Stata
11 (Stata Corporation, College Station, Texas).
Results
AMH levels in TS 0–20 years of age and
correlation with karyotype
We measured AMH in 270 patients with karyotype proven diagnosis
of TS. Patients’ characteristics are summarized in Table I. The overall
AMH was only measurable in 21.9% of TS subjects. A scatter plot of
the AMH levels in TS is depicted in Fig. 1A, which shows that
compared with healthy controls (Lie Fong et al., 2012), AMH levels
of subjects with TS were lower but some overlapped with controls.
Similar to healthy controls, there is a quadratic relationship between
age and measurable serum AMH in TS girls as shown in a logistic
model; however, the association is non-signiﬁcant (adjusted P ¼
0.07). The odds ratios (OR, adjusted for karyotype and GH
therapy) for the linear and quadratic terms of age were 1.32 (95%
CI 0.90–1.94; P ¼ 0.15) and 0.98 (95% CI 0.97–1.00; P ¼ 0.07), re-
spectively, i.e. the odds of having a measurable AMH level increased
with age when girls were young, but decreased at an older age.
Measurable AMH levels were found in 10% of TS with the karyo-
type 45,X (which comprises 50% of all TS subjects (Table II). In con-
trast, 77% of TS subjects with the karyotype 45,X/46,XX and 25% of
TS subjects with other karyotypes had measurable AMH levels. Ac-
cordingly, serum AMH levels of TS subjects were strongly correlated
with karyotype. The adjusted odds of having a measurable serum
AMH with the karyotype 45,X/46,XX was 37 times higher when
compared with the karyotype 45,X (adjusted OR 37.0; 95% CI
11.2–122.3; P, 0.001). The adjusted odds of a measurable serum
AMH was 3.4 times higher with ‘other’ karyotypes compared with
45,X (adjusted OR 3.4; 95% CI 1.6–7.2; P ¼ 0.001).
AMH and spontaneous puberty in TS
without E2 therapy
About 54% of TS subjects older than 12 years had spontaneous breast
development and 17% had a history of spontaneous menarche
(Table I). Figure 2A shows AMH levels of all TS subjects without es-
trogen replacement therapy stratiﬁed by breast development. There
was a signiﬁcant relationship between measurable serum AMH and
spontaneous breast development. Breast development was found in
91.7% of TS girls older than 12 years with measurable serum AMH
but only in 37.9% with undetectable serum AMH (Fig. 2B). As
shown in an adjusted logistic model, TS girls aged 12 years and
older had a 19.3 times increase in the odds of developing breasts
with measurable serum AMH levels (adjusted OR 19.3; 95% CI
2.1–175.6; P ¼ 0.009). Spontaneous menarche was reported in
58.3 and 2.9% of TS girls with and without measurable serum
AMH, respectively (Fig. 2C). The odds ratio of menarche in TS was
47.6 times higher with measurable AMH (crude OR 47.6; 95% CI
4.8–472.9; P ¼ 0.001).
Serum AMH in relation to FSH, LH,
E2 and inhibin B in TS without E2 therapy
The relationship between AMH and other hormones reﬂecting
gonadal function was studied in TS girls without estrogen replacement
therapy. For FSH and AMH a strong negative association was found
(Fig. 3A). The odds of a measurable AMH level was 19 times lower
if the FSH level was rising by a factor of 10 (adjusted OR 0.053;
95% CI 0.015–0.190; P, 0.001). For the subgroup of girls younger
than 12 years, the adjusted OR was comparable (0.042; 95% CI
0.007–0.240; P, 0.001). For the subgroup of girls older than
12 years, an FSH ,10 U/l predicted a measurable AMH perfectly
(therefore a logistic regression is not estimable). Similarly, we found
a negative association between LH and AMH (Fig. 3B). The odds of
a measurable AMH level was three times lower, if the LH level was
rising by a factor of 10 (adjusted OR 0.33; 95% CI 0.15–0.71; P ¼
Figure 1 Serum AMH levels in Turner syndrome (TS) girls and
adolescents with various karyotypes. (A) Absolute serum concentra-
tions of AMH (ng/ml) of 270 subjects with TS are plotted versus age
(years), stratiﬁed by karyotype. For comparison, the quadratic regres-
sion line for 252 healthy controls with a 90% prediction interval is
shown (dashed lines). (B) Log AMH values versus age, stratiﬁed by
karyotype. Non-measurable observations were assigned values of
22 on the log scale. Observations are jittered in order to better visu-
alize the distribution. AMH correlates strongly with karyotype
(adjusted P, 0.001).
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0.005). For the subgroup of girls younger than 12 years, the adjusted
OR was again comparable but non-signiﬁcant (0.48; 95% CI 0.19–
1.23; P ¼ 0.13), while it was comparable and signiﬁcant for the sub-
group of TS girls older than 12 years (adjustment not possible,
crude OR 0.08; 95% CI 0.01–0.46; P ¼ 0.005). For both serum E2
and inhibin B levels no signiﬁcant relationship with AMH levels was
found (Fig. 3C and D). This was also true for both the subgroup of
girls younger and older than 12 years.
Serum AMH levels and growth hormone
treatment
Of the TS subjects, 43.7% were receiving daily recombinant human
growth hormone (rhGH) treatment when they were studied for
their AMH levels (Table I). While most TS patients from Bern and
Tu¨bingen were under GH therapy at the time they were studied, TS
patients from Rotterdam were predominantly studied before GH
treatment starts. Thus, we tested whether GH therapy may have an
effect on serum AMH levels in TS subjects. Serum AMH levels
versus age, stratiﬁed by GH treatment are shown in Fig. 4. Without
GH therapy, 16% of TS subjects had a measurable AMH. In contrast,
with GH therapy the number of subjects with measurable serum AMH
was 30%. Accordingly, a strong relationship was found between GH
therapy and measurable AMH when adjusted for age and karyotype
in a logistic model. The odds of a measurable serum AMH were 4.1
times higher for TS with GH therapy when compared with TS
without GH therapy (OR 4.1; 95% CI 1.9–8.8; P, 0.001). Similarly,
a weak, although non-signiﬁcant, relationship was found between
measurable serum AMH and serum IGF-1 levels (taken as age-, sex
and pubertal-related standard deviation scores) when corrected for
karyotype and age in a subgroup of 73 GH-treated TS subjects from
Bern and Tu¨bingen (adjusted OR 1.63; 95% CI 0.95–2.80; P ¼ 0.08).
Discussion
Most females with TS have gonadal dysgenesis with reduced ovarian
reserve resulting in delayed or missing pubertal development, sub-
or infertility and early menopause. Quality of life is inﬂuenced by
this fact and early diagnosis and information may help to cope with
it. Cryopreservation of ovarian tissue at an early age may be consid-
ered in TS patients to preserve their own follicles for later reproduc-
tion. Serum AMH has been shown to reﬂect the ovarian reserve in
adult cycling women, and has been used as a marker for ongoing fol-
licular development in women at risk for POI (Visser et al., 2012).
Indeed, a serum AMH level in the upper normal range seems predict-
ive for ﬁnding remaining follicles in ovarian biopsies of TS girls
Figure 2 Serum AMH and puberty in TS without E2 therapy. (A) A scatter plot of AMH versus age and spontaneous breast development in TS. For
comparison, the quadratic regression line for healthy controls with a 90% prediction interval is shown (dashed lines). The odds of spontaneous breast
development are 19 times higher in TS girls older than 12 years if AMH is measurable (adjusted P, 0.009). (B) Spontaneous breast development in
41 TS subjects older than 12 years with or without measurable AMH. (C) Spontaneous menarche in 47 TS subjects older than 12 years with or
without measurable AMH. AMH, anti-Mu¨llerian hormone; TS, Turner syndrome).
AMH in Turner syndrome in childhood and adolescence 1903
(Borgstrom et al., 2009). Other predictive factors for ongoing ovarian
function in TS patients are signs of spontaneous puberty, mosaic kar-
yotype and low serum FSH (Borgstrom et al., 2009). In our 270 TS
girls and adolescents, we found detectable serum AMH levels in
22%, which correlated strongly with the karyotypes. Having a
mosaic 45,X/46,XX karyotype increased the odds of having a meas-
urable serum AMH by 37 times compared with having a 45,X karyo-
type. A positive correlation was also found between serum AMH
levels and clinical signs of pubertal development (breast, menarche).
Serum AMH was negatively related to FSH in TS girls both younger
and older than 12 years, and was negatively related to LH in girls
older than 12 years indicating that there might be a pituitary–
ovarian set point even before puberty. In contrast, no such relation-
ship was found between serum AMH and E2 or inhibin B in TS girls
without estrogen replacement therapy. Overall, our results are in
line with two previous studies. The strength of Borgstro¨m’s study
(Borgstrom et al., 2009) lies in the fact that serum AMH levels were
directly correlated with the number of ovarian follicles assessed by
histological analysis of 47 biopsies. Hagen’s study (Hagen et al.,
2010a) consisted of AMH measurements in 926 healthy and 172 TS
subjects aged 0–69 years; among them, 73 TS subjects were in the
pediatric and adolescent cohort. For TS patients, serum AMH levels
correlated with karyotype and ovarian function. We now present
similar results of the largest cohort of pediatric patients with TS so
far studied for AMH levels. Taken together all three studies suggest
that serum AMH is an excellent marker of ovarian function in girls
and adolescents with TS. The weakness of our current and published
studies lies in the cross-sectional design which does not account for
the possible dynamic changes in AMH levels of individuals over
time. For instance, we chose to group girls into prepubertal and pu-
bertal categories using a cut-off age of 12 years when 75–90% of
normal girls (Tanner and Whitehouse, 1976) and girls with TS
(Schweizer et al., 2000; Massa et al., 2003; Martin et al., 2004;
Ranke et al., 2007) would have started puberty. With this cut-off,
there is a small false-negative number of TS girls entering puberty
spontaneously later. On the other hand, more than 50% of TS girls
with spontaneous puberty onset (B ≥ 2) will not be able to complete
puberty (Reindollar, 2011) and might be ‘falsely’ included in the puber-
tal group in a cross-sectional study, thereby overestimating the
number of subjects with possible future fertility. Such shortcomings
can only be overcome in the future by performing a longitudinal
study for AMH in TS from birth to menopause.
AMH plays an important role in ovarian folliculogenesis where it is
produced in granulosa cells from birth to menopause (Visser et al.,
Figure 3 Serum AMH levels in relation to other hormonal values in TS without E2 therapy. (A) AMH versus FSH levels stratiﬁed by age. There is a
strong negative relationship between measurable AMH and log-transformed FSH as shown by a logistic model (adjusted P, 0.001). (B) Studies of
AMH versus LH levels shown as in (A). There is also a negative relationship between AMH and log-transformed LH (adjusted P ¼ 0.005).
(C) AMH and E2 levels. No relationship was found, but too many E2 values were missing (74 out of 196). (D) AMH and inhibin B. No signiﬁcant
relationship was found when adjusted for age and karyotype; however, limitations apply due to small observation numbers (72/196). AMH, anti-
Mu¨llerian hormone; TS, Turner syndrome.
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2006). In humans, AMH expression can ﬁrst be observed in granulosa
cells of primary follicles, and expression is strongest in pre-antral and
small antral follicles (≤4 mm) (Weenen et al., 2004). AMH expression
disappears in follicles of increasing size and is lost in follicles .8 mm
(Weenen et al., 2004). Serum AMH concentrations decrease over
time to become undetectable at menopause, correlating with the
decline in AFC with increasing age (de Vet et al., 2002; van Rooij
et al., 2002, 2004, 2005). In contrast, serum AMH levels increase
slightly during mini-puberty and remain constant during adolescence,
regulated through a yet unexplained mechanism (Hagen et al., 2012;
Lie Fong et al., 2012). Also in our cohort of TS subjects with measur-
able AMH, we observed a borderline quadratic relationship between
AMH and age with a rise during early childhood and a starting de-
crease in the older age group. This may suggest that follicle dynamics
in TS patients with measurable AMH is similar to that in healthy con-
trols. Recently, a prospective study in prepubertal and pubertal girls
treated for cancer demonstrated the decline in serum AMH reﬂecting
the gonadotoxic effect of the cancer treatment (Brougham et al.,
2012). Combined with that study, our results suggest that AMH
seems to be an equally good marker of ongoing follicular development
in girls, and that it therefore reﬂects the number of remaining primor-
dial follicles also in girls and adolescents with TS.
Finally, our study shows for the ﬁrst time a relationship between
rhGH therapy and serum AMH levels. AMH was detectable in 30%
of GH-treated TS girls compared with 16% without GH. Similarly,
we found a weak correlation between serum IGF-I levels and measur-
able AMH in GH-treated TS patients, although this correlation failed
to reach signiﬁcance. Several studies have suggested an important
role for the GH/IGF system in ovarian follicular development. For in-
stance, IGF-I and FSH can act synergistically to enhance follicular de-
velopment (Silva et al., 2009). In vitro studies of mouse and goat
follicles suggest that GH enhances progression of primordial to
primary follicles and stimulates follicle growth and viability (Liu et al.,
1998; Martins et al., 2010). In mice lacking GH action, the number
of healthy follicles was strongly reduced (Bachelot et al., 2002).
Thus, it is possible that GH treatment in TS patients results in
increased follicle viability, which would explain the increased percent-
age of TS girls with measurable AMH upon GH treatment. However,
GH-treated TS patients also more frequently displayed spontaneous
puberty, which is indicative of ongoing ovarian function. With our
current study design it is not possible to make a distinction between
these possible explanations. Thus, longitudinal follow-up studies are
needed to determine whether GH treatment in patients with TS is
beneﬁcial for ovarian function. Our results do suggest that GH does
not directly affect AMH levels, since there was no difference in
serum AMH levels in TS patients with or without GH treatment. Simi-
larly, in short prepubertal girls born small for gestational age serum
AMH levels were also not affected upon GH treatment and were
similar to those observed in control girls (Lem et al., 2011).
In summary, we suggest that puberty and fertility issues in patients
with TS are addressed in childhood to improve the quality of care and
to make reproductive interventions an option. Serum AMH correlates
nicely with karyotype, signs of pubertal development, LH/FSH (this
study) and ovarian follicle count (Borgstrom et al., 2009). Longitudinal
studies are needed to solve the questions whether AMH levels at a
young age are predictive, or whether multiple measurements are
needed over time; and how GH treatment inﬂuences AMH levels.
However, based on our and other studies, we suggest that serum
AMH may serve as a marker of ongoing follicular development in pre-
puberty, helping the pediatrician to deliver best possible information
on future pubertal development and fertility to TS girls and their parents.
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